- Home
- CANF vs SMTI Comparison
CANF vs SMTI Comparison
Compare CANF & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- SMTI
- Stock Information
- Founded
- CANF 1994
- SMTI 1982
- Country
- CANF Israel
- SMTI United States
- Employees
- CANF N/A
- SMTI N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- SMTI Medical/Dental Instruments
- Sector
- CANF Health Care
- SMTI Health Care
- Exchange
- CANF Nasdaq
- SMTI Nasdaq
- Market Cap
- CANF 7.9M
- SMTI 266.7M
- IPO Year
- CANF N/A
- SMTI N/A
- Fundamental
- Price
- CANF $1.17
- SMTI $31.99
- Analyst Decision
- CANF Strong Buy
- SMTI Strong Buy
- Analyst Count
- CANF 2
- SMTI 2
- Target Price
- CANF $14.00
- SMTI $48.50
- AVG Volume (30 Days)
- CANF 412.3K
- SMTI 34.9K
- Earning Date
- CANF 05-06-2025
- SMTI 05-12-2025
- Dividend Yield
- CANF N/A
- SMTI N/A
- EPS Growth
- CANF N/A
- SMTI N/A
- EPS
- CANF N/A
- SMTI N/A
- Revenue
- CANF $674,000.00
- SMTI $86,672,425.00
- Revenue This Year
- CANF $461.72
- SMTI $23.68
- Revenue Next Year
- CANF N/A
- SMTI $5.80
- P/E Ratio
- CANF N/A
- SMTI N/A
- Revenue Growth
- CANF N/A
- SMTI 33.36
- 52 Week Low
- CANF $1.22
- SMTI $25.86
- 52 Week High
- CANF $4.69
- SMTI $39.08
- Technical
- Relative Strength Index (RSI)
- CANF 37.12
- SMTI 56.57
- Support Level
- CANF $1.14
- SMTI $28.17
- Resistance Level
- CANF $1.27
- SMTI $30.37
- Average True Range (ATR)
- CANF 0.12
- SMTI 1.83
- MACD
- CANF -0.02
- SMTI 0.42
- Stochastic Oscillator
- CANF 4.46
- SMTI 100.00
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About SMTI Sanara MedTech Inc.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.